Helius Medical, Inc. Receives U.S. Marketing Authorization for the PoNS™ Device
First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, […]
Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board
Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies NEWTOWN, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the formation of a Multiple Sclerosis (“MS”) Scientific Advisory Board. The Helius MS Scientific Advisory […]
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis
NEWTOWN, Pa., May 12, 2020 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation for its PoNS™ device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (“MS”), to be used as […]